Abnormal platelet aggregation in pediatric pulmonary hypertension.

Area of Science:

• Cardiology
• Pediatric Hematology
• Pharmacology

Background:

• Prostacyclin analogs like treprostinil are used for pulmonary hypertension (PH).
• Evidence on treprostinil's effect on platelet function is conflicting.
• This study examines treprostinil's impact on platelet aggregation in pediatric PH patients.

Purpose of the Study:

• To investigate if treprostinil therapy inhibits platelet aggregation in pediatric PH patients.
• To compare platelet function in pediatric PH patients on treprostinil versus non-prostacyclin therapies.

Main Methods:

• Prospective cohort study of pediatric PH patients (≤18 years).
• Platelet function testing using light transmission aggregometry with U-46619.
• Comparison between treprostinil (TRE) and non-prostacyclin (non-TRE) therapy groups.

Main Results:

• No significant difference in abnormal platelet aggregation between TRE (44%) and non-TRE (41%) groups.
• Subgroup analysis revealed no dose-dependent effect of treprostinil.
• Moderately high rates of abnormal platelet aggregation observed in both groups.

Conclusions:

• Treprostinil therapy did not alter platelet aggregation in pediatric PH patients compared to other therapies.
• High rates of abnormal platelet aggregation in the entire cohort warrant further investigation.
• Potential inherent risk for abnormal platelet function in pediatric PH patients needs exploration.